Cullinan Therapeutics Inc (NASDAQ: CGEM) has seen a decline in its stock price by -7.42 in relation to its previous close of 17.65. However, the company has experienced a -5.17% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-09-17 that Phase 1 clinical trial is designed to assess the safety, pharmacokinetics and initial clinical activity of CLN-978 for patients with systemic lupus erythematosus
Is It Worth Investing in Cullinan Therapeutics Inc (NASDAQ: CGEM) Right Now?
Additionally, the 36-month beta value for CGEM is -0.12. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 5 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CGEM is 39.00M and currently, short sellers hold a 21.59% ratio of that float. The average trading volume of CGEM on September 26, 2024 was 716.18K shares.
CGEM’s Market Performance
The stock of Cullinan Therapeutics Inc (CGEM) has seen a -5.17% decrease in the past week, with a -10.51% drop in the past month, and a -0.97% fall in the past quarter. The volatility ratio for the week is 9.02%, and the volatility levels for the past 30 days are at 6.64% for CGEM. The simple moving average for the last 20 days is -9.35% for CGEM stock, with a simple moving average of -6.49% for the last 200 days.
Analysts’ Opinion of CGEM
Many brokerage firms have already submitted their reports for CGEM stocks, with Stifel repeating the rating for CGEM by listing it as a “Buy.” The predicted price for CGEM in the upcoming period, according to Stifel is $40 based on the research report published on May 01, 2024 of the current year 2024.
Wedbush gave a rating of “Outperform” to CGEM, setting the target price at $30 in the report published on February 15th of the current year.
CGEM Trading at -9.61% from the 50-Day Moving Average
After a stumble in the market that brought CGEM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.87% of loss for the given period.
Volatility was left at 6.64%, however, over the last 30 days, the volatility rate increased by 9.02%, as shares sank -13.36% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -14.36% lower at present.
During the last 5 trading sessions, CGEM fell by -5.17%, which changed the moving average for the period of 200-days by +101.73% in comparison to the 20-day moving average, which settled at $17.90. In addition, Cullinan Therapeutics Inc saw 60.35% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CGEM starting from Michaelson Jennifer, who sale 8,000 shares at the price of $18.09 back on Sep 05 ’24. After this action, Michaelson Jennifer now owns 115,942 shares of Cullinan Therapeutics Inc, valued at $144,720 using the latest closing price.
JENNIFER MICHAELSON & MARC D M, the Officer of Cullinan Therapeutics Inc, proposed sale 16,000 shares at $18.68 during a trade that took place back on Sep 05 ’24, which means that JENNIFER MICHAELSON & MARC D M is holding shares at $298,880 based on the most recent closing price.
Stock Fundamentals for CGEM
The total capital return value is set at -0.28. Equity return is now at value -24.60, with -23.63 for asset returns.
Based on Cullinan Therapeutics Inc (CGEM), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -46.38.
Currently, EBITDA for the company is -190.34 million with net debt to EBITDA at 0.62. The liquidity ratio also appears to be rather interesting for investors as it stands at 28.87.
Conclusion
In conclusion, Cullinan Therapeutics Inc (CGEM) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
